Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (March 2023)
28 slides from Cantargia Ab's investor presentation, March 2023
Slide 1: Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases
Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases Corporate Presentation Mar 2023 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia – Strategy to improve current cancer therapies
Cantargia – Strategy to improve current cancer therapies IL1RAP – A NOVEL TARGET WITH SEVERAL OPPORTUNITIES; CURRENT FOCUS ON SYNERGISTIC COMBINATIONS MDSC – Myeloid-Derived Suppressor Cells 3
Slide 4: New strategy to treat cancer supported by clinical results
New strategy to treat cancer supported by clinical results DATA IN PANCREATIC CANCER INDICATE SYNERGY AND CLINICAL EFFICACY Nadunolimab Durable response Primary Chemo- Short-term tumor therapy response Pancreas Resistant tumor SEVERAL LINES OF EVIDENCE SUGGEST NADUNOLIMAB COUNTERACTS CHEMORESISTANCE
Slide 5: IL1RAP: Broad application in cancer and autoimmune disease
IL1RAP: Broad application in cancer and autoimmune disease 5
Slide 6: Nadunolimab and Biological Context
NADUNOLIMAB AND BIOLOGICAL CONTEXT
Slide 7: IL1RAP overexpressed in most solid tumors
IL1RAP overexpressed in most solid tumors IL1RAP EXPRESSION IN SOLID TUMOR TYPES SEVERAL TUMOR-PROMOTING CELLS EXPRESSING IL1RAP IN THE TUMOR MICROENVIRONMENT IL1RAP-expressing tumors 100 75 50 25 0 l C C st al ic er er ta SC CL at ge ea Liv d ec ad re NS HN ha Br r nc lo Bl op Co Pa Es Cancer cell
Slide 8: Targeting IL1RAP provides unique opportunities to treat cancer by IL-1α/β blockade and ADCC
Targeting IL1RAP provides unique opportunities to treat cancer by IL-1α/β blockade and ADCC Nadunolimab NADUNOLIMAB COUNTERACTS IMMUNE SUPPRESSION AND POTENTIATES THERAPY ADCC – Antibody-Dependent Cellular Cytotoxicity; TIR – Toll-Interleukin-1 Receptor; NK – Natural Killer 8
Slide 9: Nadunolimab potentiates antitumor activity of chemotherapy
Nadunolimab potentiates antitumor activity of chemo- therapy Nadunolimab IL-1α Tumor growth * 20 100 Relative expression Tumor volume (%) 15 ** Control Docetaxel 10 50 Anti-IL-1β + Docetaxel Nadunolimab + Docetaxel 5 0 0 4 500 Docetaxel (nM) → Nadunolimab blocks both IL-1α and → Docetaxel induces IL
Slide 10: Chemotherapy induces IL-1α and IL-1β in the tumor
Chemotherapy induces IL-1α and IL-1β in the tumor IL-1α IL-1β-converting enzyme Tumor cell region (T) Stromal cell region (S) 6 * Control Gem/Cis 250 ** Control Gem/Cis 2 Positive cells/mm % Positive cells S 200 T T 4 T 150 S S 100 2 S T T 50 T 0 0 l s t ro Ci is l / ro n /C Co Gem nt m Co Ge → Gem/
Slide 11: Targeting IL1RAP uniquely synergizes with chemotherapy
Targeting IL1RAP uniquely synergizes with chemotherapy Tumor growth Body weight 2000 0 Tumor volume (mm ) 3 1500 Vehicle % Change Iso Control -5 Vehicle 1000 Nadunolimab Gem/Cis Gem/Cis ** Nadunolimab+Gem/Cis Nadunolimab+Gem/Cis -10 500 * 0 -15 0 5 10 15 Day post-treatment → Nadunolimab increases ef
Slide 12: Induction of IL1RAP and IL-1α with therapy in NSCLC pts
Induction of IL1RAP and IL-1α with therapy in NSCLC pts Pretreatment On treatment (Nadunolimab + Gem/Cis) IL1RAP (brown) IL-1α (brown) IL-1ALPHA INDUCED BY CHEMOTHERAPY IN LINE WITH PRECLINICAL FINDINGS; WELL ESTABLISHED DANGER SIGNAL – ACTIVITY BLOCKED BY NADUNOLIMAB 12
Slide 13: PDAC staging and treatment
PDAC staging and treatment Expected number of cases US 2023: 64000 Stage I - local: 3200 Stage II - regional LN; 3200 Stage IV - Stage III - metastatic: locally adv: 32000 25600 Stage I Stage II Stage III Stage IV RESECTABLE OR BORDERLINE RESECTABLE DISEASE LOCALLY ADVANCED OR METASTATIC DISEASE Sur
Slide 14: Positive interim data in 1st line pancreatic cancer
Positive interim data in 1st line pancreatic cancer Nadunolimab combination with Gem/Abraxane in 1st line (n=73): → 33% response rate with long PFS and OS → Additional 5 (7%) pts had on-treatment benefit beyond progression → Promising PFS (7.2 mo), DCR (73%) and OS (12.7 mo1) → 12 pts still on treat
Slide 15: Safety profile is manageable and supports MOA
Safety profile is manageable and supports MOA → Neutropenia manageable through G-CSF prophylaxis → In 7 pts given G-CSF prophylaxis, only 1 developed grade 3-4 neutropenia All Patients in All Cycles → Only 1 % peripheral neuropathy grade 3-4 observed (17% in historical controls) 100% n=6 n=15 Grade
Slide 16: Combination strategy in NSCLC – Promising efficacy
Combination strategy in NSCLC – Promising efficacy Nadunolimab combination with Gem/Cis in 1st/2nd line: → 16 of 30 pts with objective response incl. 1 complete response (ORR 53%) (historical control data of 22-28%) → Generally well tolerated; neutropenia freq. higher than expected from chemo (manag
Slide 17: Strong signal in 1st/2nd line non-squamous NSCLC
Strong signal in 1st/2nd line non-squamous NSCLC Nadunolimab combination with Gem/Cis in 1st/2nd line non-squamous NSCLC: → Approx. 75% of all NSCLC cases → 9 of 16 evaluable pts had objective response including 1 complete response (ORR 56%) (historical control data of 19%) → 8 pts were 2nd line to
Slide 18: Promising early safety and efficacy in TNBC
Promising early safety and efficacy in TNBC Nadunolimab combination with Gem/Carbo in 100 % 1st/2nd line metastatic TNBC: Best change in tumor size 15 pts enrolled in the dose-escalation phase 50 % → Acceptable safety profile PD (G-CSF given prophylactically to control neutropenia) SD 0% → 12 pts tr
Slide 19: Key messages
Key messages → Most chemotherapies induce chemoresistance already after Resistant a few months of therapy. Chemotherapy can upregulate tumor Chemo- both IL-1α and IL-1β. therapy → Unlike other IL-1 blocking compounds, nadunolimab blocks both IL-1α and IL-1β signalling and improves chemotherapy effic
Slide 20: CAN10 Opportunity in Autoimmune/Inflammatory Disease
CAN10 OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 21: CAN10 – New asset within autoimmunity/inflammation
CAN10 – New asset within autoimmunity/inflammation → IL1RAP-binding antibody potently blocking IL-1, IL-33 and IL-36, without ADCC → Unique anti-inflammatory activity observed in different mouse models (myocarditis, systemic sclerosis, psoriasis, inflammation) → Development focusing on systemic scle
Slide 22: CAN10 – Promising effects in several preclinical disease models
CAN10 – Promising effects in several preclinical disease models Viral myocarditis Disease severity Autoimmune myocarditis Cardiac function 4 *** 1.1 Ratio to baseline * ** 3 1.0 * mCAN10 Ctrl mCAN10 Score 2 0.9 Anti-IL-1β Ctrl Anti-IL-1β Vehicle 1 0.8 0 0.7 0 10 20 30 40 cle A l 0 ro 1R N1 Day nt hi
Slide 23: CAN10 – Project status
CAN10 – Project status GLP toxicity study – Completed → CAN10 given i.v. once weekly for six weeks at doses up to 50 mg/kg or s.c. at 5 mg/kg → No adverse findings related to CAN10 at/above clinically relevant (pharmacologically active) dose levels Clinical phase I study – Study start planned for H1
Slide 24: Financials, Milestones & Summary
FINANCIALS, MILESTONES & SUMMARY
Slide 25: Planned next steps
Planned next steps Nadunolimab PDAC NSCLC TNBC CAN10 • Start Phase II/III • Explore development • Randomized phase II • Submit application to Precision Promise℠ trial into randomized trial in stage in TRIFOUR: regulatory authorities with PanCAN non-squamous subtype Interim futility analysis to start
Slide 26: Several upcoming value inflection points
Several upcoming value inflection points Newsflow over next quarters Nadunolimab (CAN04) → Update of results for PDAC, NSCLC, TNBC and Keytruda combination → Start phase II/III Precision Promise℠ (PDAC) → New preclinical and translational results → New clinical data (efficacy and safety) • CAPAFOUR
Slide 27: Solid financial position with strong shareholder support
Solid financial position with strong shareholder support → Cash and cash equivalents SEK 427 M (~$41M) at end of Q4 2022 Current owners (Dec 31, 2022) → Operating expenses SEK 382 M (~$37M) in 2022 4th AP fund 8.8% • R&D - 96% of operating expenses Alecta 7.3% • 27 full-time employees • Market cap a
Slide 28: Cantargia: Investment highlights
Cantargia: Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO ADDRESS CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • Potential to breakdown resistance to cancer treatment, enabled by unique dual action approach – nadunolimab • Additional key target for inf